Study of factors predicting the efficacy of abatacept in patients with rheumatoid arthritis
Not Applicable
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000042329
- Lead Sponsor
- niversity of Occupational and Environmental Health, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 111
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with a history of allergy to any component of abatacept 2) Patients with complication by malignant tumor 3) Patients with active infection or hepatitis B and HB carrier 4) Pregnant women, lactating women or women desiring pregnancy, child delivery or breast-feeding 5) Patients judged as inappropriate for this study by Principal Investigator or Sub-investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Achievement rate of DAS28-CRP> 1.2 improvement 12 months after abatacept administration
- Secondary Outcome Measures
Name Time Method 1) Identification of subgroups the patients according to their abnormality patterns in both SNP existence and baseline immune-phenotype profiles 2) Identification of patient subgroups for which abatacept is more efficacious